Tawanda Gumbo

List of Publications by Year in Descending Order

161 papers	6,752 citations	45 h-index	77 g-index
170 ext. papers	7,954 ext. citations	8.4 avg, IF	6.04 L-index

#	Paper	IF	Citations
161	Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.. *Antimicrobial Agents and Chemotherapy*, **2022**, e0232021	5.9	0
160	Repurposing Cefazolin-Avibactam for the Treatment of Drug Resistant. *Frontiers in Pharmacology*, **2021**, 12, 776969	5.6	0
159	Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration. *International Journal of Infectious Diseases* , **2021**, 104, 680-684	10.5	1
158	Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model. *Journal of Global Antimicrobial Resistance*, **2021**, 24, 403-410	3.4	1
157	Nouveau short-course therapy and morphism mapping for clinical pulmonary. *Antimicrobial Agents and Chemotherapy*, **2021**,	5.9	2
156	Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis. *International Journal of Infectious Diseases*, **2021**, 105, 688-694	10.5	6
155	Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis. *European Respiratory Journal*, **2021**, 57,	13.6	
154	Comparison of Rifamycins for Efficacy Against Complex and Resistance Emergence in the Hollow Fiber Model System. *Frontiers in Pharmacology*, **2021**, 12, 645264	5.6	2
153	Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against. *Frontiers in Pharmacology*, **2021**, 12, 677005	5.6	3
152	Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse. *Communications Biology*, **2021**, 4, 664	6.7	3
151	Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients. *Antimicrobial Agents and Chemotherapy*, **2021**, 65, e0027821	5.9	1
150	Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children. *Pediatric Infectious Disease Journal*, **2020**, 39, 1092-1100	3.4	3
149	Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis. *Nature Medicine*, **2020**, 26, 1435-1443	50.5	15
148	Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions. *Nature Medicine*, **2020**, 26, 529-534	50.5	43
147	Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 1212-1217	5.1	17
146	Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 392-399	5.1	7
145	Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis. *International Journal of Audiology*, **2020**, 59, 219-223	2.6	3

144	A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guﾨin. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 1277-1291	10.2	9
143	Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	3
142	sncRNA-1 Is a Small Noncoding RNA Produced by in Infected Cells That Positively Regulates Genes Coupled to Oleic Acid Biosynthesis. *Frontiers in Microbiology*, **2020**, 11, 1631	5.7	2
141	Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2020**, 65,	5.9	6
140	Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone. *Antimicrobial Agents and Chemotherapy*, **2020**, 64,	5.9	6
139	Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis. *Clinical Infectious Diseases*, **2020**, 70, 1774-1780	11.6	32
138	Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating. *Frontiers in Pharmacology*, **2020**, 11, 616294	5.6	2
137	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. *Lancet Respiratory Medicine,the*, **2019**, 7, 820-826	35.1	49
136	Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 370-380	10.2	19
135	Detectable prednisolone is delayed in pericardial fluid, compared with plasma of patients with tuberculous pericarditis: A pilot study. *IJC Heart and Vasculature*, **2019**, 22, 105-110	2.4	
134	Quantitative assessment of the activity of antituberculosis drugs and regimens. *Expert Review of Anti-Infective Therapy*, **2019**, 17, 449-457	5.5	0
133	Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1952-1961	5.1	13
132	Once-a-week tigecycline for the treatment of drug-resistant TB. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 1607-1617	5.1	3
131	Dosing tuberculosis drugs in young children: the road ahead. *The Lancet Child and Adolescent Health* , **2019**, 3, 590-592	14.5	
130	Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 2994-3002	5.1	1
129	Minocycline Immunomodulates via Sonic Hedgehog Signaling and Apoptosis and Has Direct Potency Against Drug-Resistant Tuberculosis. *Journal of Infectious Diseases*, **2019**, 219, 975-985	7	7
128	Pan-tuberculosis regimens: an argument against. *Lancet Respiratory Medicine,the*, **2018**, 6, 240-242	35.1	10
127	Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment. *International Journal of Infectious Diseases*, **2018**, 68, 18-23	10.5	10

126	Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs. *Clinical Infectious Diseases*, **2018**, 67, 1743-1749	11.6	16
125	Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 1208-1219	10.2	68
124	Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	19
123	Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges. *Clinical Infectious Diseases*, **2018**, 67, S349-S358	11.6	15
122	Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis. *Clinical Infectious Diseases*, **2018**, 67, S274-S283	11.6	18
121	Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis. *Clinical Infectious Diseases*, **2018**, 67, S342-S348	11.6	14
120	Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary Tuberculosis. *Clinical Infectious Diseases*, **2018**, 67, S284-S292	11.6	12
119	Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. *Clinical Infectious Diseases*, **2018**, 67, S293-S302	11.6	46
118	Linezolid-based Regimens for Multidrug-resistant Tuberculosis (TB): A Systematic Review to Establish or Revise the Current Recommended Dose for TB Treatment. *Clinical Infectious Diseases*, **2018**, 67, S327-S335	11.6	31
117	Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs. *Clinical Infectious Diseases*, **2018**, 67, S267-S273	11.6	20
116	Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!. *Clinical Infectious Diseases*, **2018**, 67, S359-S364	11.6	10
115	Ethionamide Pharmacokinetics/Pharmacodynamics-derived Dose, the Role of MICs in Clinical Outcome, and the Resistance Arrow of Time in Multidrug-resistant Tuberculosis. *Clinical Infectious Diseases*, **2018**, 67, S317-S326	11.6	19
114	d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal. *Clinical Infectious Diseases*, **2018**, 67, S308-S316	11.6	26
113	The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis. *Clinical Infectious Diseases*, **2018**, 67, S336-S341	11.6	18
112	Clofazimine for the Treatment of Mycobacterium kansasii. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	10
111	Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 2020-2027	5.1	4
110	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. *Lancet Respiratory Medicine,the*, **2017**,	35.1	313
109	pH Conditions under Which Pyrazinamide Works in Humans. *Antimicrobial Agents and Chemotherapy* , **2017**, 61,	5.9	3

108	Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science. *Lancet Infectious Diseases, The*, **2017**, 17, 898	25.5	6
107	Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis. *Science Advances*, **2017**, 3, e1701102	14.3	41
106	Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	64
105	Sterilizing Effect of Ertapenem-Clavulanate in a Hollow-Fiber Model of Tuberculosis and Implications on Clinical Dosing. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	20
104	Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation. *British Journal of Clinical Pharmacology*, **2017**, 83, 801-811	3.8	14
103	The discovery of ceftazidime/avibactam as an anti-Mycobacterium avium agent. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i36-i42	5.1	23
102	Reply to Raoult. *Clinical Infectious Diseases*, **2017**, 64, 984	11.6	4
101	Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis. *Clinical Infectious Diseases*, **2017**, 64, 1350-1359	11.6	32
100	Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i3-i19	5.1	34
99	Linezolid as treatment for pulmonary Mycobacterium avium disease. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i24-i29	5.1	15
98	Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i30-i35	5.1	26
97	A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i48-i53	5.1	22
96	A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i43-i47	5.1	12
95	A programme to create short-course chemotherapy for pulmonary Mycobacterium avium disease based on pharmacokinetics/pharmacodynamics and mathematical forecasting. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i54-i60	5.1	7
94	Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, i20-i23	5.1	7
93	Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	57
92	Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation. *PLoS ONE*, **2017**, 12, e0187624	3.7	8
91	Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 269-281	35.1	80

90	Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 6374-6	5.9	36
89	Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5928-32	5.9	36
88	Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo. *Clinical Infectious Diseases*, **2016**, 63, S88-S94	11.6	28
87	A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. *Clinical Infectious Diseases*, **2016**, 63, S95-S101	11.6	35
86	Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. *Clinical Infectious Diseases*, **2016**, 63, S102-S109	11.6	27
85	Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests. *Clinical Infectious Diseases*, **2016**, 63, S63-S74	11.6	74
84	A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground. *Clinical Infectious Diseases*, **2016**, 63, S75-S79	11.6	12
83	Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps. *Clinical Infectious Diseases*, **2016**, 63, S80-S87	11.6	32
82	Partnerships to Design Novel Regimens to Treat Childhood Tuberculosis, Sui Generis: The Road Ahead. *Clinical Infectious Diseases*, **2016**, 63, S110-S115	11.6	6
81	Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 5922-7	5.9	24
80	Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 4652-8	5.9	24
79	A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies. *EBioMedicine*, **2016**, 6, 126-138	8.8	35
78	Azithromycin Dose To Maximize Efficacy and Suppress Acquired Drug Resistance in Pulmonary Mycobacterium avium Disease. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2157-63	5.9	20
77	Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. *BMC Infectious Diseases*, **2016**, 16, 242	4	10
76	Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2895-900	5.9	39
75	Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3779-85	5.9	19
74	Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3193-5	5.9	16
73	The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism. *EBioMedicine*, **2016**, 11, 118-126	8.8	13

72	Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 38-45	5.9	91
71	Acquired drug resistance: we can do more than we think!. *Clinical Infectious Diseases*, **2015**, 60, 969-70	11.6	15
70	Reply to "breakpoints and drug exposure are inevitably closely linked". *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1385	5.9	
69	Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments. *Clinical Infectious Diseases*, **2015**, 61 Suppl 1, S10-7	11.6	44
68	Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm. *Clinical Infectious Diseases*, **2015**, 61 Suppl 1, S18-24	11.6	46
67	Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes. *Clinical Infectious Diseases*, **2015**, 61 Suppl 1, S25-31	11.6	60
66	Nonclinical models for antituberculosis drug development: a landscape analysis. *Journal of Infectious Diseases*, **2015**, 211 Suppl 3, S83-95	7	63
65	Fatal Lure of Look-Back Studies in Explaining Pharmacological Events Such as Acquired Drug Resistance in Patients With Multidrug-Resistant Tuberculosis. *Journal of Infectious Diseases*, **2015**, 212, 166-7	7	1
64	Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality. *EBioMedicine*, **2015**, 2, 1634-9	8.8	20
63	Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6337-43	5.9	49
62	Comment on: Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 320-1	5.1	4
61	Amikacin Pharmacokinetics/Pharmacodynamics in a Novel Hollow-Fiber Mycobacterium abscessus Disease Model. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1242-8	5.9	30
60	Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 2273-9	5.9	15
59	Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. *Journal of Infectious Diseases*, **2015**, 211 Suppl 3, S96-S106	7	74
58	Single or 2-Dose Micafungin Regimen for Treatment of Invasive Candidiasis: Therapia Sterilisans Magna!. *Clinical Infectious Diseases*, **2015**, 61 Suppl 6, S635-42	11.6	13
57	Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis. *EBioMedicine*, **2015**, 2, 1640-8	8.8	19
56	Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 1115-23	5.1	45
55	Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. *Lancet Respiratory Medicine,the*, **2014**, 2, 321-38	35.1	191

54	Redefining multidrug-resistant tuberculosis based on clinical response to combination therapy. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 6111-5	5.9	46
53	Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. *BMC Infectious Diseases* , **2014**, 14, 115	4	13
52	Acquired drug resistance because of pharmacokinetic variability in a young child with tuberculosis. *Pediatric Infectious Disease Journal*, **2014**, 33, 1205	3.4	5
51	Modeling and simulation for medical product development and evaluation: highlights from the FDA-C-Path-ISOP 2013 workshop. *Journal of Pharmacokinetics and Pharmacodynamics*, **2014**, 41, 545-52	2.7	16
50	The pyrazinamide susceptibility breakpoint above which combination therapy fails. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 2420-5	5.1	48
49	Drug concentration monitoring in Mycobacterium avium lung disease: problems with methods and conclusions. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 554-5	10.2	0
48	Serum drug concentrations predictive of pulmonary tuberculosis outcomes. *Journal of Infectious Diseases*, **2013**, 208, 1464-73	7	296
47	Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congeners. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5870-7	5.9	34
46	Weight drives caspofungin pharmacokinetic variability in overweight and obese people: fractal power signatures beyond two-thirds or three-fourths. *Antimicrobial Agents and Chemotherapy*, **2013** , 57, 2259-64	5.9	36
45	Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 1115-20	5.9	14
44	A meta-analysis of self-administered vs directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. *Clinical Infectious Diseases*, **2013**, 57, 21-31	11.6	80
43	The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 4806-15	5.9	126
42	Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. *Clinical Infectious Diseases*, **2012**, 55, 169-77	11.6	152
41	New susceptibility breakpoints and the regional variability of MIC distribution in Mycobacterium tuberculosis isolates. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 5428	5.9	16
40	Mycobacterial shuttle vectors designed for high-level protein expression in infected macrophages. *Applied and Environmental Microbiology*, **2012**, 78, 6829-37	4.8	7
39	Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1502-7	5.9	27
38	Scientific and patient care evidence to change susceptibility breakpoints for first-line anti-tuberculosis drugs. *International Journal of Tuberculosis and Lung Disease*, **2012**, 16, 706-7	2.1	4
37	Reply to Pharmacokinetic Mismatch of Tuberculosis Drugs *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1667-1667	5.9	78

36	A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. *Current Opinion in Pharmacology*, **2011**, 11, 457-63	5.1	64
35	Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium. *Future Microbiology*, **2011**, 6, 433-9	2.9	10
34	Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 5085-9	5.9	40
33	An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 24-34	5.9	87
32	In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 539-45	5.9	25
31	Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. *Journal of Infectious Diseases*, **2011**, 204, 1951-9	7	205
30	In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. *Current Pharmaceutical Design*, **2011**, 17, 2881-8	3.3	30
29	Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 5107-12	5.9	39
28	Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2534-9	5.9	41
27	New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1484-91	5.9	111
26	Clinical and toxicodynamic evidence that high-dose pyrazinamide is not more hepatotoxic than the low doses currently used. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2847-54	5.9	51
25	Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. *Journal of Infectious Diseases*, **2010**, 201, 1225-31	7	98
24	Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium avium. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 1728-33	5.9	49
23	Meningeal tuberculosis: high long-term mortality despite standard therapy. *Medicine (United States)*, **2010**, 89, 189-195	1.8	28
22	Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy*, **2009**, 29, 1468-81	5.8	50
21	Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 3197-204	5.9	151
20	Population pharmacokinetics of micafungin in adult patients. *Diagnostic Microbiology and Infectious Disease*, **2008**, 60, 329-31	2.9	61
19	Anidulafungin in the treatment of invasive fungal infections. *Therapeutics and Clinical Risk Management*, **2008**, 4, 71-8	2.9	11

18	Integrating pharmacokinetics, pharmacodynamics and pharmacogenomics to predict outcomes in antibacterial therapy. *Current Opinion in Drug Discovery & Development*, **2008**, 11, 32-42		6
17	Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. *Clinical Infectious Diseases*, **2007**, 44, 79-86	11.6	523
16	Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3781-8	5.9	262
15	Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. *Journal of Infectious Diseases*, **2007**, 195, 194-201	7	79
14	Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 3714-9	5.9	85
13	Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 2329-36	5.9	126
12	Reply to Wallis et al. and Mitchison et al.. *Journal of Infectious Diseases*, **2007**, 195, 1872-1873	7	7
11	Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 968-74	5.9	95
10	Impact of pharmacodynamics and pharmacokinetics on echinocandin dosing strategies. *Current Opinion in Infectious Diseases*, **2007**, 20, 587-91	5.4	29
9	Glucan Synthase Inhibitors. *Infectious Disease and Therapy*, **2007**, 355-378		1
8	The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations. *Clinical Infectious Diseases*, **2006**, 42, 525-32	11.6	46
7	Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 3695-700	5.9	63
6	Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 5058-68	5.9	145
5	Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 3178-81	5.9	68
4	Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. *Journal of Infectious Diseases*, **2004**, 190, 1642-51	7	267
3	Late complications of Candida (Torulopsis) glabrata fungemia: description of a phenomenon. *Scandinavian Journal of Infectious Diseases*, **2002**, 34, 817-8		11
2	Clinicopathological features of cutaneous histoplasmosis in human immunodeficiency virus-infected patients in Zimbabwe. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **2001**, 95, 635-6	2	10
1	Candida glabrata Fungemia. Clinical features of 139 patients. *Medicine (United States)*, **1999**, 78, 220-7	1.8	66